Gustavo Viani: Induction Chemotherapy vs. Stantard Chemoradiotherapy in Locally Advanced Cervical Cancer
Gustavo Viani shared on LinkedIn:
“Short-course induction chemotherapy by chemoradiotherapy significantly increases survival of patients with locally advanced cervical cancer‼️
Objective:
• Investigate if adding induction chemotherapy to standard chemoradiotherapy high progression-free survival and overall survival in participiants with locally advanced cervical cancer
Methods:
• Phase 3 multicentre, randomized trial
• Participiants: 500 patients with FIGO stage IB1 (with nodal involvement) to IVA cervical cancer, randomized 1:1.
• Intervention:
• Standard cisplatin-based chemoradiotherapy.
• Induction chemotherapy (carboplatin + paclitaxel) followed by chemoradiotherapy.
• Key endpoints: Progression-free survival (PFS) and overall survival (OS).
Results:
• 5-year PFS: 72% (induction chemo group) vs. 64% (chemoradiotherapy group)
• 5-year OS: 80% (induction chemo group) vs. 72% (chemoradiotherapy group)
• Induction chemotherapy significantly high both PFS (HR 0.65, p=0.013) and OS (HR 0.60, p=0.015)
• Grade 3+ adverse events were high in the induction chemotherapy group (59% vs. 48%).”
Authors: Mary McCormack, Gemma Eminowicz, Dolores Gallardo, Patricia Diez, Laura Farrelly, Christopher Kent, Emma Hudson, Miguel Panades, Tony Mathew, Anjana Anand, Mojca Persic, Jennifer Forrest, Rajanee Bhana, Nicholas Reed, Anne Drake, Madhavi Adusumalli, Asima Mukhopadhyay, Margaret King, Karen Whitmarsh, John McGrane, Nicoletta Colombo, Choi Mak, Ranajit Mandal, Rahul Roy Chowdhury, Gabriela Alamilla-Garcia, Adriana Chávez-Blanco, Hilary Stobart, Amanda Feeney, Simran Vaja, Anne-Marie Hacker, Allan Hackshaw, Jonathan Andrew Ledermann,
More posts featuring Gustavo Viani on oncodaily.com
Gustavo Viani, MD is an Associate Professor in the Department of Medical Imaging, Hematology, and Oncology at Hospital das Clínicas, Faculty of Medicine of Ribeirão Preto, University of São Paulo (FMRP-USP). Dr. Viani’s research focuses on radiation oncology, with expertise in brachytherapy, stereotactic radiosurgery, dose fractionation, radiation tolerance, and overall oncology practices.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023